Marc Sapoval

Marc Sapoval

Auto-generated profile, based on publicly available information

Marc Sapoval

Department of Vascular and Oncological Interventional Radiology, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, 75015 Paris, France; Université Paris Cité, Inria, Inserm, HeKA, PR[AI]RIE-PSAI, 75015 Paris, France

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in The Lancet
Verified
Journal Article
Closed access
MAMichel Azizi
Michel Azizi
MSMarc Sapoval
Marc Sapoval
PGPhilippe Gosse
Philippe Gosse
MMMatthieu Monge
Matthieu Monge
GBGuillaume Bobrie
Guillaume Bobrie
RIRenal Denervation for Hypertension (DENERHTN) investigators
Renal Denervation for Hypertension (DENERHTN) investigators

1 May 2011 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
JBJean-Pierre Becquemin
Jean-Pierre Becquemin
JPJean-Chistophe Pillet
Jean-Chistophe Pillet
FLFrançois Lescalie
François Lescalie
MSMarc Sapoval
Marc Sapoval
YGYann Goueffic
Yann Goueffic
ATAce Trialists
Ace Trialists

3 February 2017 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
JPJ T Powell
J T Powell
MSM J Sweeting
M J Sweeting
PUP Ulug
P Ulug
JBJ D Blankensteijn
J D Blankensteijn
FLF A Lederle
F A Lederle
CCC Cousins
C Cousins
The erosion of the early mortality advantage of elective endovascular aneurysm repair (EVAR) compared with open repair of abdominal aortic aneurysm remains without a satisfactory explanation. An individual-patient data meta-analysis of four multicentre randomized trials of EVARversus open repair was conducted to a prespecified analysis plan, reporting on mortality, aneurysm-related mortality and reintervention. The analysis included 2783 patients, with 14 245 person-years of follow-up (median 5·5 years). Early (0–6 months after randomization) mortality was lower in the EVAR groups (46 of 1393 versus 73 of 1390 deaths; pooled hazard ratio 0·61, 95 per cent c.i. 0·42 to 0·89; P = 0·010), primarily because 30-day operative mortality was lower in the EVAR groups (16 deaths versus 40 for open repair; pooled odds ratio 0·40, 95 per cent c.i. 0·22 to 0·74). Later (within 3 years) the survival curves converged, remaining converged to 8 years. Beyond 3 years, aneurysm-related mortality was significantly higher in the EVAR groups (19 deaths versus 3 for open repair; pooled hazard ratio 5·16, 1·49 to 17·89; P = 0·010). Patients with moderate renal dysfunction or previous coronary artery disease had no early survival advantage under EVAR. Those with peripheral artery disease had lower mortality under open repair (39 deaths versus 62 for EVAR; P = 0·022) in the period from 6 months to 4 years after randomization. The early survival advantage in the EVAR group, and its subsequent erosion, were confirmed. Over 5 years, patients of marginal fitness had no early survival advantage from EVAR compared with open repair. Aneurysm-related mortality and patients with low ankle : brachial pressure index contributed to the erosion of the early survival advantage for the EVAR group. Trial registration numbers: EVAR-1, ISRCTN55703451; DREAM (Dutch Randomized Endovascular Aneurysm Management), NCT00421330; ACE (Anévrysme de l'aorte abdominale, Chirurgie versus Endoprothèse), NCT00224718; OVER (Open Versus Endovascular Repair Trial for Abdominal Aortic Aneurysms), NCT00094575.

1 September 2010 in Hypertension
Verified
Journal Article
Closed access
LTLudovic Trinquart
Ludovic Trinquart
CMClaire Mounier-Vehier
Claire Mounier-Vehier
MSMarc Sapoval
Marc Sapoval
NGNathalie Gagnon
Nathalie Gagnon
PPPierre-FrançoIs Plouin
Pierre-FrançoIs Plouin
In patients with fibromuscular dysplasia and renal artery stenosis, renal artery revascularization has been used to cure hypertension or to improve blood pressure control. To provide an up-to-date assessment of the benefits and risks associated with revascularization in this condition, we performed a systematic review of studies in which hypertensive patients with fibromuscular dysplasia renal artery stenosis underwent percutaneous transluminal renal angioplasty or surgical reconstruction. We assessed how often periprocedural complications and hypertension cure and improvement occurred. We selected 47 angioplasty studies (1616 patients) and 23 surgery studies (1014 patients). Combined rates of hypertension cure, defined according to the criteria in each study, after angioplasty or surgery were estimated to be 46% (95% CI: 40% to 52%) and 58% (95% CI: 53% to 62%), respectively, with substantial variations across studies. The probability of being cured was negatively associated with patient age and time of publication. Cure rates using current definitions of hypertension cure (blood pressure <140/90 mm Hg without treatment) were only 36% and 54% after angioplasty and surgery, respectively. The combined risks of periprocedural complications were 12% and 17% after angioplasty and surgery, respectively, with less major complications after angioplasty than surgery (6% versus 15%). In conclusion, angioplasty or surgical revascularization yielded moderate benefits in patients with fibromuscular dysplasia renal artery stenosis, with substantial variation across studies. The blood pressure outcome was strongly influenced by patient age.

1 July 2014 in Journal Of Hypertension
Verified
Journal Article
Closed access
APAlexandre Persu
Alexandre Persu
AGAlessandra Giavarini
Alessandra Giavarini
ETEmmanuel Touzé
Emmanuel Touzé
AJAndrzej Januszewicz
Andrzej Januszewicz
MSMarc Sapoval
Marc Sapoval
PLPeter de Leeuw
Peter de Leeuw
The main objectives of this expert consensus are to raise awareness about fibromuscular dysplasia, which is more frequent and more often systemic than previously thought and can sometimes have devastating consequences; to provide up-to-date recommendations for the diagnosis, evaluation, and management of the disease; and to identify research priorities. The emphasis has been put on recommendations for daily practice. The main topics covered include definition, classification, diagnosis, and management of fibromuscular dysplasia in adult patients with symptomatic involvement of the renal arteries, supra-aortic trunks, and digestive and peripheral arteries.

20 September 2016 in Circulation
Verified
Journal Article
Closed access
MAMichel Azizi
Michel Azizi
HPHelena Pereira
Helena Pereira
IHIdir Hamdidouche
Idir Hamdidouche
PGPhilippe Gosse
Philippe Gosse
MMMatthieu Monge
Matthieu Monge
DIDENERHTN Investigators
DENERHTN Investigators
Background: The DENERHTN trial (Renal Denervation for Hypertension) confirmed the blood pressure–lowering efficacy of renal denervation added to a standardized stepped-care antihypertensive treatment for resistant hypertension at 6 months. We report the influence of adherence to antihypertensive treatment on blood pressure control. Methods: One hundred six patients with hypertension resistant to 4 weeks of treatment with indapamide 1.5 mg/d, ramipril 10 mg/d (or irbesartan 300 mg/d), and amlodipine 10 mg/d were randomly assigned to renal denervation plus standardized stepped-care antihypertensive treatment, or the same antihypertensive treatment alone. For standardized stepped-care antihypertensive treatment, spironolactone 25 mg/d, bisoprolol 10 mg/d, prazosin 5 mg/d, and rilmenidine 1 mg/d were sequentially added at monthly visits if home blood pressure was ≥135/85 mm Hg after randomization. We assessed adherence to antihypertensive treatment at 6 months by drug screening in urine/plasma samples from 85 patients. Results: The numbers of fully adherent (20/40 versus 21/45), partially nonadherent (13/40 versus 20/45), or completely nonadherent patients (7/40 versus 4/45) to antihypertensive treatment were not different in the renal denervation and the control groups, respectively ( P =0.3605). The difference in the change in daytime ambulatory systolic blood pressure from baseline to 6 months between the 2 groups was –6.7 mm Hg ( P =0.0461) in fully adherent and –7.8 mm Hg ( P =0.0996) in nonadherent (partially nonadherent plus completely nonadherent) patients. The between-patient variability of daytime ambulatory systolic blood pressure was greater for nonadherent than for fully adherent patients. Conclusions: In the DENERHTN trial, the prevalence of nonadherence to antihypertensive drugs at 6 months was high (≈50%) but not different in the renal denervation and control groups. Regardless of adherence to treatment, renal denervation plus standardized stepped-care antihypertensive treatment resulted in a greater decrease in blood pressure than standardized stepped-care antihypertensive treatment alone. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01570777.